5 Top Performing Healthcare Companies Financial Metrics Stock Performance 2026 Tips Every Investor Needs
The top performing healthcare companies financial metrics stock performance 2026 story is not about which drug had the best sales quarter. It is about which businesses generate durable returns on capital, carry manageable risk, and trade at prices a disciplined investor can justify. Healthcare is the S&P 500's third-largest sector by weight, and it spans a wide range of business models, from asset-light pharmaceutical royalty companies to capital-intensive hospital networks with unpredictable reimbursement exposure.
This list focuses on five names that stand out on quality, valuation, and risk metrics as of April 2026. The selection criteria: ROIC above 15%, max drawdown over 12 months below the sector average of 28%, and a P/E ratio supported by earnings growth rather than multiple expansion.
Key Takeaways
- Healthcare is one of the least cyclical sectors in the S&P 500, which keeps max drawdown relatively contained during broad market selloffs.
- Johnson & Johnson (JNJ) remains the quality archetype: P/E near 15.4, dividend yield of 3.1%, and a business that generates consistent free cash flow regardless of economic conditions.
- The best healthcare stocks in 2026 share one trait: high return on invested capital with a low correlation to GDP growth, which is the definition of durable competitive advantage.
- Beta below 0.7 is common among quality healthcare names, making the sector a natural diversifier for high-beta technology-heavy portfolios.
- ValueMarkers tracks P/E, max drawdown, and beta for healthcare stocks across 73 global exchanges, letting you screen the global sector rather than just U.S. names.
- Valuation discipline matters in healthcare the same as everywhere else: a great business bought at 40 times earnings can still underperform a mediocre one bought at 10 times earnings over a five-year horizon.
Why Healthcare Outperforms During Market Stress
Healthcare demand does not compress meaningfully in recessions. People do not defer insulin or cancer treatment when the economy slows. This demand inelasticity produces earnings stability that translates into lower beta and smaller drawdowns than the broad market.
During the 2022 market correction, when the S&P 500 fell approximately 19%, the healthcare sector fell about 3.5%. In 2020, when equities dropped 34% at the March low, healthcare held substantially better than consumer discretionary, energy, or financials.
The sector is not immune to selloffs. Regulatory risk, pricing pressure from Medicare negotiation, and clinical trial failures can hit individual names hard. But at the index level, healthcare is the closest the stock market gets to a defensive growth asset.
Top Performing Healthcare Companies: 2026 Ranking
The five companies below are evaluated on a consistent set of metrics: trailing P/E, ROIC, dividend yield, 12-month max drawdown, and beta versus the S&P 500. All data is approximate as of April 2026.
| Company | Ticker | P/E | ROIC | Dividend Yield | 12-Month Max Drawdown | Beta |
|---|---|---|---|---|---|---|
| Johnson & Johnson | JNJ | 15.4 | 18.2% | 3.1% | -12.4% | 0.55 |
| UnitedHealth Group | UNH | 22.1 | 21.8% | 1.5% | -31.2% | 0.72 |
| Eli Lilly | LLY | 58.3 | 38.6% | 0.6% | -26.8% | 0.49 |
| Abbott Laboratories | ABT | 26.7 | 14.9% | 1.8% | -15.1% | 0.66 |
| Medtronic | MDT | 18.9 | 11.4% | 3.4% | -11.8% | 0.59 |
The spread across this table illustrates a central tension in healthcare investing: the highest ROIC names (Eli Lilly at 38.6%) often trade at the highest multiples (P/E of 58.3), while the most attractively valued names (JNJ at 15.4 P/E) tend to have lower, though still respectable, capital returns.
1. Johnson & Johnson: The Quality Benchmark
JNJ is the reference point for quality in healthcare. Its P/E near 15.4 is the lowest on this list and below the sector average. Its dividend has grown for over 60 consecutive years, which makes it one of fewer than 70 companies with Dividend King status.
The business generates free cash flow reliably across economic cycles. The pharmaceutical division (now separated from consumer health as Kenvue) focuses on specialty drugs with pricing power. MedTech provides a more commoditized but stable revenue stream.
The 3.1% yield at a payout ratio below 50% means the dividend is well covered and has room to grow even if earnings compress temporarily. For income-focused portfolios, JNJ is the most defensible starting point in the sector.
Max drawdown over the past 12 months sits around 12.4%, well below the sector average. Beta near 0.55 means JNJ moves roughly half as much as the S&P 500 on a given day, which is the profile you want in a defensive anchor position.
2. UnitedHealth Group: Capital Efficiency at Scale
UNH operates the largest private health insurance and healthcare services business in the U.S. Its ROIC of 21.8% is the second highest on this list, reflecting a business model built on data advantages, scale, and tight cost management through Optum, its integrated health services arm.
The trailing P/E near 22.1 sits above JNJ but below the S&P 500 median for large-cap healthcare. The 12-month max drawdown of 31.2% reflects specific UNH risks: regulatory uncertainty around Medicare Advantage reimbursement and ongoing legal exposure from a cyberattack on Change Healthcare in 2024.
Despite the drawdown, the underlying business fundamentals remain intact. Revenue per member is growing. Optum's operating margin continues to expand. For investors who can hold through regulatory noise, UNH's ROIC and scale create a durable earnings base.
3. Eli Lilly: The Growth Premium in Healthcare
LLY is not a value stock. At a P/E near 58.3, it carries one of the highest multiples in the S&P 500. The premium reflects a singular opportunity: GLP-1 drugs (tirzepatide under brands Mounjaro and Zepbound) for obesity and diabetes represent a once-in-a-generation pharmaceutical platform.
The ROIC of 38.6% justifies paying above-average multiples if the growth runway is real, and the available evidence suggests it is. Global obesity affects over 1 billion people and penetration of GLP-1 drugs remains below 5% of the eligible population.
The risk is concentration. If a competitor undercuts pricing, a safety signal emerges, or payer coverage contracts, LLY's multiple compresses rapidly. The 12-month max drawdown of 26.8% captures some of that volatility. LLY suits investors with a three-to-five year horizon and tolerance for premium-multiple risk. It does not suit investors who need income or low volatility.
4. Abbott Laboratories: Diversified Medical Device Quality
ABT straddles four business segments: diagnostics, medical devices, established pharmaceuticals in emerging markets, and nutrition. That diversification reduces the revenue concentration risk that plagues pure-play pharmaceutical names.
ROIC near 14.9% is below the threshold we set as ideal (15%), but Abbott's consistent free cash flow generation and disciplined capital allocation keep it on this list. The P/E near 26.7 reflects a moderate growth premium that its MedTech and diagnostics businesses have historically earned.
The 12-month max drawdown of 15.1% and beta of 0.66 confirm its defensive character. The 1.8% dividend yield is lower than JNJ or Medtronic but the payout ratio gives the company significant room to compound the dividend over time.
5. Medtronic: Deep Value in Medical Devices
MDT is the most undervalued name on this list by conventional metrics. At a P/E near 18.9 and a dividend yield of 3.4%, it offers the highest income alongside a valuation significantly below the sector median.
The max drawdown of 11.8% over 12 months is the lowest on this list, reflecting that the stock has already de-rated meaningfully over several years of execution challenges. MDT's ROIC of 11.4% is the lowest here, which explains the discount. The company has struggled with new product cycles in its spine and cardiac rhythm divisions.
The bull case is a mean-reversion story: a business with $30+ billion in revenue, a 3.4% yield, and a management team that has committed to margin improvement and capital allocation discipline. The bear case is that ROIC stays below 12% as revenue growth remains muted. Value investors who can tolerate uncertainty on the execution timeline get paid 3.4% annually to wait.
What Happens If the Stock Market Crashes
Healthcare historically falls less than the broad market during crashes, but it is not crash-proof. The degree of protection depends on the type of downturn.
In demand-shock recessions (2008 to 2009), healthcare fell roughly 23% peak to trough while the S&P 500 fell 57%. In rate-shock selloffs (2022), healthcare fell under 5% while the S&P 500 fell 19%. In pandemic-induced crashes (March 2020), healthcare fell about 25% versus the S&P 500's 34%.
The pattern is consistent: healthcare defends better in every crash scenario but does not provide complete protection. Names with strong balance sheets (low debt-to-equity) and essential products (insulin, cancer drugs) hold better than device companies or elective-procedure-dependent businesses.
Further reading: SEC EDGAR · FRED Economic Data
Why best healthcare stocks 2026 Matters
This section anchors the discussion on best healthcare stocks 2026. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply best healthcare stocks 2026 in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for best healthcare stocks 2026
See the main discussion of best healthcare stocks 2026 in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using best healthcare stocks 2026 alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for best healthcare stocks 2026
See the main discussion of best healthcare stocks 2026 in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using best healthcare stocks 2026 alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Pe Ratio — Glossary entry for Pe Ratio
- Maximum Drawdown 1Y (Max Drawdown) — Maximum Drawdown 1Y expresses the financial stress or solvency profile of the business
- Beta — Glossary entry for Beta
- Portfolio Management Software — related ValueMarkers analysis
- Sp 500 History Performance — related ValueMarkers analysis
- Nuclear Energy Stocks — related ValueMarkers analysis
Frequently Asked Questions
what happens if the stock market crashes
When the stock market crashes, equity prices fall broadly and quickly, often driven by forced selling, margin calls, or a fundamental shift in earnings expectations. Healthcare stocks historically fall less than the broad market during crashes due to inelastic demand for medical products and services. JNJ fell roughly 23% in 2008 to 2009 versus the S&P 500's 57% decline. Investors holding quality healthcare names with strong balance sheets and essential products typically experience smaller drawdowns and faster recoveries.
what time does the stock market open
The U.S. stock market (NYSE and Nasdaq) opens at 9:30 a.m. Eastern Time on weekdays. Pre-market trading runs from approximately 4:00 a.m. to 9:30 a.m. Eastern, and after-hours trading runs from 4:00 p.m. to 8:00 p.m. Eastern. Healthcare stocks frequently move during pre-market hours on earnings releases and clinical trial data announcements, which are often scheduled before the regular session opens.
are stock markets closed today
U.S. stock markets close on federal holidays including New Year's Day, Martin Luther King Jr. Day, Presidents' Day, Good Friday, Memorial Day, Juneteenth, Independence Day, Labor Day, Thanksgiving, and Christmas Day. Markets also close early (at 1:00 p.m. Eastern) on the day after Thanksgiving and on Christmas Eve when it falls on a weekday. Check the NYSE or Nasdaq official holiday schedule for the exact dates each year.
what time does the stock market close
The U.S. stock market closes at 4:00 p.m. Eastern Time on regular trading days. After-hours trading continues until 8:00 p.m. Eastern. Healthcare earnings releases, FDA approval announcements, and clinical trial results frequently arrive after 4:00 p.m., meaning the full market reaction appears at the next day's open rather than in the closing price.
when does the stock market open
The New York Stock Exchange and Nasdaq open at 9:30 a.m. Eastern Time Monday through Friday, excluding federal holidays. Pre-market activity begins at 4:00 a.m. Eastern for most brokerages. The first 30 minutes after the 9:30 a.m. open tend to see the highest volume and widest bid-ask spreads as the market processes overnight news, including pharmaceutical and medical device company announcements.
why is the stock market down today
The stock market falls on any given day for a combination of reasons: rising interest rates reduce the present value of future earnings, disappointing earnings reports lower near-term growth expectations, geopolitical events create uncertainty, or broad risk-off sentiment causes institutional investors to reduce equity exposure. Healthcare stocks are sometimes down on specific regulatory news (Medicare pricing changes, FDA rejections) even when the rest of the market is flat. Check individual news catalysts before attributing a single stock's decline to broad market moves.
Screen all five of these healthcare names alongside 73 global exchanges using our portfolio tracker to compare their current P/E, ROIC, and max drawdown against your existing holdings in real time.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.